ong-term observational study of Gene Therapy for Sporadic ALS
Not Applicable
Recruiting
- Conditions
- Sporadic amyotrophic lateral sclerosis (Sporadic ALS)
- Registration Number
- JPRN-jRCT2033230284
- Lead Sponsor
- Morita Mitsuya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Patients who enrolled in the Phase I/II Study of Gene Therapy for Sporadic ALS, and who completed or discontinued the study.
Exclusion Criteria
-Patients who are judged by the investigator or subinvestigator to be inappropriate to participate in this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the long-term tolerability, safety, and efficacy of the study product in patients with Sporadic ALS, after medullary cavity administrations of AAV.GTX-ADAR2.
- Secondary Outcome Measures
Name Time Method